ADAM9 and Decreased total leukocyte count: Therefore, we developed an optimized ADAM9-responsive MSN (OPT-MSN) and assessed the potential clinical applicability of these OPT-MSNs by addressing the potential cytotoxicity on key cell types involved in neurotoxicity and leukopenia, as well as their efficacy in a PDAC xenograft model.